iRhythm Technologies Stock Price, News & Analysis (NASDAQ:IRTC)

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for iRhythm Technologies in the last year. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" IRTC shares.
View IRTC analyst ratings or view top-rated stocks.

8 equities research analysts have issued 1-year price objectives for iRhythm Technologies' stock. Their IRTC share price targets range from $100.00 to $165.00. On average, they predict the company's share price to reach $131.33 in the next twelve months. This suggests a possible upside of 51.2% from the stock's current price.
View analysts price targets for IRTC or view top-rated stocks among Wall Street analysts.

iRhythm Technologies' stock was trading at $93.67 on January 1st, 2023. Since then, IRTC shares have decreased by 7.3% and is now trading at $86.87.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 22nd 2024.
View our IRTC earnings forecast.

iRhythm Technologies, Inc. (NASDAQ:IRTC) posted its quarterly earnings data on Thursday, November, 2nd. The company reported ($0.89) EPS for the quarter, missing analysts' consensus estimates of ($0.65) by $0.24. The company had revenue of $124.60 million for the quarter, compared to the consensus estimate of $122.46 million. iRhythm Technologies had a negative trailing twelve-month return on equity of 46.35% and a negative net margin of 22.19%.

ETFs with the largest weight of iRhythm Technologies (NASDAQ:IRTC) stock in their portfolio include Global X Telemedicine & Digital Health ETF (EDOC), Fidelity Digital Health ETF (FDHT), ROBO Global Healthcare Technology and Innovation ETF (HTEC), SPDR S&P Health Care Equipment ETF (XHE), ROBO Global Robotics & Automation ETF (ROBO), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), BNY Mellon Innovators ETF (BKIV) and Fidelity Disruptive Medicine ETF (FMED).

20 employees have rated iRhythm Technologies Chief Executive Officer Kevin M. King on Glassdoor.com. Kevin M. King has an approval rating of 91% among the company's employees. This puts Kevin M. King in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other iRhythm Technologies investors own include NVIDIA (NVDA), Alibaba Group (BABA), Salesforce (CRM), Block (SQ), Teladoc Health (TDOC), Trade Desk (TTD), Advanced Micro Devices (AMD), Intel (INTC), Broadcom (AVGO) and Boeing (BA).

(IRTC) raised $76 million in an IPO on Thursday, October 20th 2016. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan and Morgan Stanley served as the underwriters for the IPO and Canaccord Genuity and BTIG were co-managers.

iRhythm Technologies' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Sands Capital Management LLC (7.67%), Artisan Partners Limited Partnership (6.40%), Mackenzie Financial Corp (4.13%), JPMorgan Chase & Co. (4.02%), Blair William & Co. IL (3.63%) and FMR LLC (2.78%). Insiders that own company stock include Daniel G Wilson, David A Vort, Douglas Devine, Kevin M King, Mark J Day, Merz Cathleen Noel Bairey, Patrick Michael Murphy and Quentin S Blackford.
View institutional ownership trends.

Shares of IRTC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.